Relax-AHF-EU

A multicenter, prospective, randomized, open label study to assess the effect of serelaxin versus standard of care in acute heart faiure (AHF) patients

16/09/2016 to 18/09/2017

The aim of this study is to assess the efficacy, safety and tolerability of intravenous infusion of 30 µg/kg/day serelaxin administered for 48 hours when added to standard therapy in patients hospitalized for acute heart failure. Efficacy will be determined based on the combined primary endpoint of in-hospital worsening of heart failure requiring rescue therapy and all-cause death through day 5. Patients will be followed-up for 30 days.

The aim of this study is to generate clinical evidence, especially on the short-term period (in-hospital and at 30 days) that wil complement existing and fututre serelaxin data sets in AHF.